ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SNG Synairgen Plc

4.51
-0.135 (-2.91%)
Last Updated: 11:53:49
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.135 -2.91% 4.51 4.41 4.99 4.53 4.51 4.53 189,892 11:53:49
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -17.65M -0.0876 -0.51 9.35M
Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 4.65p. Over the last year, Synairgen shares have traded in a share price range of 3.65p to 10.62p.

Synairgen currently has 201,345,000 shares in issue. The market capitalisation of Synairgen is £9.35 million. Synairgen has a price to earnings ratio (PE ratio) of -0.51.

Synairgen Share Discussion Threads

Showing 14551 to 14574 of 99175 messages
Chat Pages: Latest  583  582  581  580  579  578  577  576  575  574  573  572  Older
DateSubjectAuthorDiscuss
20/7/2020
08:28
Mentioned on Sky News - 'game changer'
grafter
20/7/2020
08:26
Dabbled some of my profits into DDDD seems an obvious choice to piggyback profits with 12 trials in progress. What a day.
tidy 2
20/7/2020
08:25
from FINNCAP UpgradesSynairgen (SNG LN/AIM/£55m) – Positive results from trial in COVID patientsSynairgen has released very positive results from its Phase II trial of SNG001 in hospitalised COVID-19 patients.The results were clear and unambiguous with three clear points:79% reduction in patients developing severe disease or death.Those on SNG001 more than twice as likely to recover over the treatment period than those on placebo.There was also a 'statistically significant' reduction in breathlessness.Synairgen will discuss with the regulators how to progress SNG001 as rapidly as possible, but the prospect of generating sales in 2020 is considered increasingly likely.The prospect of governments using SNG001 as a broad spectrum antiviral treatment that should be stockpiled for future pandemics or used routinely to treat seasonal winter infections is also becoming increasingly likely.Part of the fundraise we completed in April was to increase manufacturing capacity so that by end August, Synairgen should be able to produce thousands of doses per month.The COPD study that Synairgen is undertaking should have results in August and this data enhances the prospect of this being positive too.Recommendation: Corporate. Target Price – 360p (up from 120p)
maccamcd
20/7/2020
08:24
Show some nerve and Hold this is going Ballistic
thwarnts
20/7/2020
08:22
I'm so pleased my mum has COPL and it will help her perhaps and the virus situation too.

Very well done SNG staff!

hazl
20/7/2020
08:22
Great, well done to holders here, now can we roll this drug out nationally and start getting on with the OLD NORMAL again. Or does the government really want that?
katsy
20/7/2020
08:21
Take care selling SNG as MMs are offering very mixed prices. Took £1.05 for 15% of my holding - an offer seconds earlier was just 75p.
noirua
20/7/2020
08:20
SnG great results and ODX any time.Will do the same imo
36jay
20/7/2020
08:18
:)) lovely
g2theary
20/7/2020
08:17
This will settle at about 240 today. The strength of the result bodes very well for home trial and also big pharma buy out. Spring coiling again
slinkyj
Chat Pages: Latest  583  582  581  580  579  578  577  576  575  574  573  572  Older